Oncology
Anktiva Expands for Papillary-Only Bladder Cancer
The FDA expanded Anktiva plus BCG to adults with BCG-unresponsive, high-grade papillary non-muscle-invasive bladder cancer without carcinoma in situ.
Rayan Salih · November 13, 2026 · 6 min
Living with bladder cancer
Stories from people navigating bladder cancer — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Oncology
FDA Expands Anktiva Plus BCG Approval to Papillary-Only Bladder Cancer
The FDA expanded Anktiva plus BCG to adults with BCG-unresponsive, high-grade papillary-only non–muscle-invasive bladder cancer, adding a bladder-preserving option for this underserved group.
Dr. Abu Bakar · 7 min read
Other conditions
One story a day
The story of the day, in your inbox
One health journey each morning — no advice, no alarm, just company for the road.